// App-Quantinova.ai

S311 : ESTIMATED HOSPITALIZATION-RELATED COSTS WITH ORAL AZACITIDINE (ORAL-AZA) VS PLACEBO (PBO) FOR REMISSION MAINTENANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN SPAIN AND THE UNITED KINGDOM (UK)

Researchers

Presenter

  • Christopher Pocock

Principal Investigators

  • Pau Montesinos

  • Thorsten Braun

  • Suman Kambhampati

  • Albert Oriol

  • Ignazia La Torre

  • Barry Skikne

  • CL Beach

  • Jianhua Zhong

  • Clara Chen

  • Sandip Ranjan

  • Ravi Potluri

  • Esther Natalie Oliva

Medical Centers

  • SmartAnalyst India (Pvt.) Ltd, Gurgaon, India

  • VA Medical Center,Kansas City,United States

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Kent & Canterbury Hospital, Kent, United Kingdom

  • Sarah Cannon at Research Medical Center,Kansas City,United States

  • SmartAnalyst, Inc. New York NY United States

  • Hematology Department,Institut Català d’Oncologia and Josep Carreras Institute, Hospital Germans Trias i Pujol,Barcelona,Spain

  • Hopital Avicenne -Paris 13 University, Bobigny, France

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Kansas University Medical Center, Kansas City, KS

  • Bristol Meyers Squibb,Princeton,United States

  • Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

  • Kent &amp

Locations

  • India

  • United States

  • Spain

  • United Kingdom

  • France

  • Switzerland

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved